XELJANZ XR (tofacitinib) extended-release tablets

XELJANZ/XELJANZ XR is a brand-name prescription drug that’s FDA-approved to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. XELJANZ XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 2012

Home | (tofacitinib) extended-release tablets

XELJANZ XR (tofacitinib) extended-release tablets Price In India and Overseas
XELJANZ XR (tofacitinib) extended-release tablets

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Overseas Patient/ Export inquires.

Call / WhatsApp Number
+91 9643240915 (Mr. Yashpal Singh)
+91 9289711087 (Ms. Sana Sadyar)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

XELJANZ XR (tofacitinib) extended-release tablets

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

XELJANZ/XELJANZ XR is a prescription medicine called a Janus kinase (JAK) inhibitor.
XELJANZ/XELJANZ XR is used to treat adults with moderately to severely active rheumatoid arthritis in
whom methotrexate did not work well.
XELJANZ/XELJANZ XR is used to treat adults with active psoriatic arthritis in which methotrexate or other
similar medicines called nonbiologic disease-modifying antirheumatic drugs (DMARDs) did not work well.
XELJANZ is used to treat adults with moderately to severely active ulcerative colitis.
It is not known if XELJANZ/XELJANZ XR is safe and effective in people with Hepatitis B or C.
XELJANZ/XELJANZ XR is not recommended for people with severe liver

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.

Rheumatoid arthritis
Tofacitinib citrate is approved for medical use in the United States with an indication “to treat adults with moderately to severely active rheumatoid arthritis.” In the European Union, in combination with methotrexate, tofacitinib citrate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA).

Ulcerative colitis
In May 2018, the FDA approved tofacitinib citrate “for the treatment of adult patients in the U.S. with moderately to severely active ulcerative colitis.” Tofacitinib citrate is the first oral JAK inhibitor approved for use in chronic ulcerative colitis.

Drug (Brand / Generic): XELJANZ XR / tofacitinib tablets
Current Indications: rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
Marketed by:: National Institutes of Health and Pfizer.
Approval Date: 2012

Available as (Form & Strength): XELJANZ Tablets: 5 mg, 10 mg tofacitinib, XELJANZ XR Tablets: 11 mg tofacitinib.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.